BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to commence a Phase IIa trial for its BL-8040 Leukemia drug. The primary endpoints are safety and tolerability. BLRX lost over half its market cap in March after discontinuing a clinical trial for an antipsychotic. Shares +7% premarket.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs